Cliantha Research acquires Inflamax Research
Cliantha Research is proud to announce the acquisition of Inflamax Research. Inflamax has locations in Toronto, ON, Neptune, NJ and Newark, NJ. Cliantha Research will have the capabilities to perform Phase I, II, III and IV clinical research in North America. The patented natural allergen Environmental Exposure Chambers (EEC) shall allow Cliantha to conduct Asthma, Allergy, Ophthalmology, Tobacco research plus specialized pulmonary/respiratory therapeutic studies. The two New Jersey clinics were acquired by Hill Top Research (St. Petersburg, FL), a wholly owned subsidiary of Cliantha Research since 2011. With two clinical sites in the U.S., Hill Top Research can conduct HRIPT studies as per FDA guidance. Both firms are committed to a smooth, well planned integration of services in North America and India. The synergy of the combined companies expands service offerings and will drive growth.